

Preliminary Final Report

For the year ended 30 June 2021

Mediland Pharm Limited Appendix 4E Preliminary final report

1. Company details

Name of entity: Mediland Pharm Limited

ABN: 83 628 420 824

Reporting period: For the year ended 30 June 2021 For the year ended 30 June 2020

2. Results for announcement to the market

			\$
Revenues from ordinary activities	down	95.0% to	1,157,489
Loss from ordinary activities after tax attributable to the owners of Mediland Pharm Limited	Up	25.86% to	6,430,453
Loss for the year attributable to the owners of Mediland Pharm Limited	Up	25.86% to	6,430,453

Dividends

There were no dividends paid, recommended or declared during the current financial period. The directors do not propose to pay a final dividend for the year ended 30 June 2021.

Comments

Mediland's operations continued with significant disruption as a result of COVID-19 pandemic, with the Group focusing on preserving its cash position and controlling its costs.

The loss for the consolidated entity after providing for income tax and non-controlling interest amounted to \$6,430,453 (30 June 2020: \$5,109,041). The loss after tax was attributable to the following:

- As indicated in previous period reports, the Company underwent a substantial decrease in revenue from ordinary activities as the full impact of the Covid-19 pandemic was felt. There had been nil income from retail stores since suspension of trading in February 2020. With continued suspended retail operations for most of 2020 calendar year, all Australian subsidiaries were entered into external administration in December 2020.
- After seeking non-associated shareholders' approval in April 2021, the Company purchased the Hamilton Hotel in New Zealand. The revenue includes two months of trading from hotel operations since its date of acquisition with an average occupancy rate of 78%.
 - Impairment expense increased from \$nil to \$3.4m. The decrease was mainly attributable to closure of all retail stores since the announcement of the pandemic.

The Company has implemented rigorous cost control measures and has stabilised cashflows used in operations by minimising fixed operating costs. During the financial year, the Company terminated four of six lease contracts resulting in a substantial decrease in on-going occupancy and operational expenses.

Management remains open to once again playing an active role in the "health and well-being" sector in the inbound Chinese tourist retail market as and when the tourism industry returns to some form of normality.

3. Net tangible assets

r F	porting period Cents	Previous period Cents
Net tangible assets per ordinary security	0.03	0.03

4. Control gained over entities

Name of entities (or group of entities)
IXORA Investments Limited (New Zealand)
The Collection Hotels and Resorts Pty Ltd (Sydney)

Date control gained 29 April 2021 27 April 2021

5. Loss of control over entities

Name of entities (or group of entities)
Darling Harbour Pty Ltd (Sydney store)
St Wells Pty Ltd (Melbourne store)
Surfers Paradise Pty Ltd (Gold Coast store)
Enti Financial Ltd (Sydney store)
Share We Do Platform Technology Services Co., Ltd (China)

Date control lost
11 December 2020
11 December 2020
11 December 2020
12 May 2021
23 June 2021

6. Details of associates and joint venture entities

None

7. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements are based on the accounts that is in the progress of being audited.

8. Attachments

Details of attachments (if any):

Consolidated statement of profit or loss and other comprehensive income Consolidated statement of financial position Consolidated Statement of cash flows Consolidated statement of changes in equity

Mediland Pharm Limited Appendix 4E Preliminary final report

9. Signed

Dr Peter French Chairman

Sydney 31 August 2021 Yeshween Mudaliar Managing Director

Sydney 31 August 2021

Afroi

Mediland Pharm Limited Consolidated statement of profit or loss and other comprehensive income For the year ended 30 June 2021

		Consolidated		
	2021	2020		
	\$	\$		
Revenue	1,157,489	23,298,447		
Cost of sales	(541,369)	(5,506,738)		
		(0,000,00)		
Gross profit	616,120	17,791,709		
Other income	139,627	109,722		
Government grant	629,753	288,984		
Gain on loss of control of subsidiaries	1,844,206	-		
Gain on lease termination	449,581	-		
Gain on bargain purchase	355,675	-		
	(04.000)			
Bad debts	(91,000)	-		
Inventory written off	(392,397)	- (4E 266 EE0)		
Marketing expenses	(18,501)	(15,366,550)		
Occupancy expenses	(2.102.692)	(437,675)		
Administrative expenses	(2,102,682)	(3,439,141)		
Employee benefit expenses Share-based payment expenses	(1,151,014) (552,311)	(2,697,129) (990,560)		
Finance costs	(141,291)	(180,527)		
Impairment expenses	(3,461,248)	(100,327)		
Loan forgiveness on the loss of control	(3,134,450)	_		
(Loss) before income tax expense	(7,009,932)	(4,921,167)		
Income tax (expense)/benefit	563,354	(187,874)		
Loss after income tax expense for the year	(6,446,578)	(5,109,041)		
Attributable to:				
Owners of Mediland Pharm Limited	(6,430,453)	(5,109,041)		
Non-controlling interests	(16,125)	-		
Loss after income tax expense for the year	(6,446,578)	(5,109,041)		
	Cents	Cents		
Earnings	(0.00)	(4.00)		
Basic earnings per share	(2.03)	(1.63)		
Diluted earnings per share	(2.03)	(1.63)		
Other comprehensive loss				
Items that may be reclassified subsequently to profit or loss				
Foreign currency translation	(9,782)	(72,723)		
	(0,102)	(12,120)		
Other comprehensive loss for the year, net of tax	(9,782)	(72,723)		
Total comprehensive loss for the year	(6,456,360)	(5,181,764)		
		_		
Attributable to:				
Owners of Mediland Pharm Limited	(6,440,235)	(5,181,764)		
Non-controlling interests	(16,125)	<u>-</u>		
	(6, 456,360)	(5,181,764)		

Mediland Pharm Limited Consolidated statement of financial position As at 30 June 2021

Assets		Consoli 2021	2020
Current assets 3,391,075 7,304,139 Cash and cash equivalents 377,148 925,029 Prepayments 15,278 - Inventories 81,097 1,411,204 Current tax assets - 373,842 Total current assets 10,014,214 Non-current assets - 3,864,598 10,014,214 Non-current assets - 3,953,146 11,014,305 3,953,146 Initiangibles 18,733 204,647 3,953,146 11,873 204,647 3,953,146 Goodwill 5,724,624 8,525,423 1,014,350 1		\$	\$
Cash and cash equivalents 3,391,075 7,304,139 925,029 Trade and other receivables 377,148 925,029 Prepayments 15,278 1 Inventories 81,097 1,411,204 Current tax assets 3,364,598 10,014,214 Non-current assets 81,097 1,411,204 Non-current assets 5,723,691 3,031,398 Right-of-use assets 18,733 20,464 Goodwill 2,873,404 2,852,423 Total received tax assets 5,742,424 8,525,623 Total assets 9,607,022 18,539,637 Liabilities 5,742,424 8,525,623 Total assets 9,607,022 18,539,637 Liabilities 804,885 3,704,391 Frovisions 61,384 50,854 Current liabilities 61,384 50,854 Lease – Short term liabilities 65,363 9,999,987 Current tax liabilities 2,494,674 4,975,683 Total current liabilities 2,494,674 4,975,683 <th>Assets</th> <th></th> <th></th>	Assets		
Cash and cash equivalents 3,391,075 7,304,139 925,029 Trade and other receivables 377,148 925,029 Prepayments 15,278 1 Inventories 81,097 1,411,204 Current tax assets 3,364,598 10,014,214 Non-current assets 81,097 1,411,204 Non-current assets 5,723,691 3,031,398 Right-of-use assets 18,733 20,464 Goodwill 2,873,404 2,852,423 Total received tax assets 5,742,424 8,525,623 Total assets 9,607,022 18,539,637 Liabilities 5,742,424 8,525,623 Total assets 9,607,022 18,539,637 Liabilities 804,885 3,704,391 Frovisions 61,384 50,854 Current liabilities 61,384 50,854 Lease – Short term liabilities 65,363 9,999,987 Current tax liabilities 2,494,674 4,975,683 Total current liabilities 2,494,674 4,975,683 <td>Current assets</td> <td></td> <td></td>	Current assets		
Trace and other receivables 377,148 925,029 Prepayments 15,278 - Inventories 81,097 1,411,204 Current tax assets 3,864,598 10,014,214 Non-current assets - 3,73,642 Property, plant, and equipment 5,723,691 3,953,146 Right-of-use assets 18,733 204,647 Goodwill - 3,953,146 Intargibles 18,733 204,647 Goodwill - 3,963,146 Intargibles 18,733 204,647 Goodwill - 3,963,146 Intargibles 18,733 204,647 Goodwill - 3,21,882 Total non-current assets 9,607,022 18,539,637 Liabilities - 1,143,50 Trade and other payables 804,885 3,704,391 Trade and other payables 61,384 50,854 Current tax liabilities 65,363 - Lease – Short term liabilities 2,494,674 4,975,683 <		3 391 075	7 304 139
Prepayments	·		
Inventoriores			-
Current tax assets 373,842 Total current assets 3,864,598 10,014,214 Non-current assets 10,014,214 Property, plant, and equipment 5,723,691 3,031,398 Right-of-use assets 18,733 3,953,146 intangibles 18,733 204,647 Goodwill - 321,882 Deferred tax assets 5,742,424 8,525,423 Total assets 9,607,022 18,539,637 Liabilities - 10,14,350 Total assets 804,885 3,704,391 Total assets 804,885 3,704,391 Use of more deposit 804,885 3,704,391 Current liabilities 65,333 -9 Current liabilities 65,333 -9 Current liabilities 412,572 20,451 Eorrowings – Short term liabilities 2,494,674 4,975,683 Non-current liabilities 2,494,674 4,975,683 Provisions 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224		· · · · · · · · · · · · · · · · · · ·	1.411.204
Total current assets		-	
Non-current assets		3,864,598	
Property, plant, and equipment 5,723,691 3,031,388 Right-of-use assets 18,733 204,647 Goodwill 2,321,882 Deferred tax assets -,1014,350 Total non-current assets 5,742,424 8,525,423 Total assets 9,607,022 18,539,637 Liabilities Trade and other payables 804,885 3,704,391 Provisions 61,384 50,854 Customer deposit - 399,987 Current tax liabilities 65,363 - Lease – Short term liabilities 412,572 820,451 Borrowings – Short term liabilities 4,944,674 4,975,683 Non-current liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease – Long term liabilities 3,505,322 Total inon-current liabilities 2,80,658 8,774,672 Net assets 2,80,658 8,774,672 Net assets 2,886,384 9,764,965 Fequity <t< td=""><td></td><td></td><td>, ,</td></t<>			, ,
Right-of-use assets	Non-current assets		
Right-of-use assets		5,723,691	3,031,398
Condwill		<u>-</u>	3,953,146
Deferred tax assets	Intangibles	18,733	204,647
Total non-current assets 5,742,424 8,525,423 Total assets 9,607,022 18,539,637 Liabilities Current liabilities Trade and other payables 804,885 3,704,391 Provisions 61,384 50,854 Customer deposit - 399,987 Current tax liabilities 65,363 - Lease - Short term liabilities Lease - Short term liabilities 1,150,470 - Total current liabilities Borrowings - Short term liabilities 2,494,674 4,975,683 Non-current liabilities 2,494,674 4,975,683 Deferred tax liabilities 245,971 1,398,224 Lease - Long term liabilities 245,971 1,398,224 Lease - Long term liabilities 3,505,322 - Total non-current liabilities Total inon-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Non-current liabilities 2,186,367 1,643,838 Reserves 2,186,367 1,643,838	Goodwill	-	321,882
Total assets 9,607,022 18,539,637 Liabilities Current liabilities Trade and other payables 804,885 3,704,391 Provisions 61,384 50,854 Curson deposit - 399,987 Current tax liabilities 65,363 - Lease – Short term liabilities 412,572 820,451 Borrowings – Short term liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease – Long term liabilities 245,971 1,398,224 Lease – Long term liabilities 249,397 3,391,058 Borrowings – Long term liabilities 3,505,322 2 Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Lequity 11,898,945 11,898,945 11,898,945 14,388,945 Reserves 2,186,367 1,643,838 4,241,690 4,788,111 Lequity 11,198,5641	Deferred tax assets		1,014,350
Liabilities Current liabilities 804,885 3,704,391 Provisions 61,384 50,854 Customer deposit - 399,987 Current tax liabilities 65,363 - Lease – Short term liabilities 412,572 820,451 Borrowings – Short term liabilities 1,150,470 Total current liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease – Long term liabilities 245,971 1,398,224 Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 4,241,690 4,789,282 Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Lequity 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090)	Total non-current assets	5,742,424	8,525,423
Current liabilities Trade and other payables 804,885 3,704,391 Provisions 61,384 50,854 Customer deposit - 399,987 Current tax liabilities 65,363 - 399,987 Lease – Short term liabilities 412,572 820,451 Borrowings – Short term liabilities 1,150,470 - 70 Total current liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 3,505,322 - 7 Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Lequity 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -	Total assets	9,607,022	18,539,637
Trade and other payables 804,885 3,704,391 Provisions 61,384 50,854 Customer deposit - 399,987 Current tax liabilities 65,363 - Lease – Short term liabilities 412,572 820,451 Borrowings – Short term liabilities 1,150,470 - Total current liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 3,505,322 - Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity Issued capital 11,898,945 1,888,945 Reserves 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -	Liabilities		
Provisions 61,384 50,854 Customer deposit - 399,987 Current tax liabilities 65,363 Lease – Short term liabilities 412,572 820,451 Borrowings – Short term liabilities 1,150,470 Total current liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 3,505,322 4,789,282 Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity Issued capital 11,898,945 1,898,945 Reserves 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -	Current liabilities		
Customer deposit Current tax liabilities - 399,987 Current tax liabilities 65,363 - Borrowings – Short term liabilities 1,150,470 - Total current liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 3,505,322 - Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity 11,898,945 11,898,945 11,898,945 Issued capital 11,898,945 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -			
Current tax liabilities 65,363 - Lease - Short term liabilities 412,572 820,451 Borrowings - Short term liabilities 1,150,470 - Total current liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease - Long term liabilities 490,397 3,391,058 Borrowings - Long term liabilities 3,505,322 - Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity 11,898,945 11,898,945 Reserves 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -		61,384	
Lease – Short term liabilities 412,572 820,451 Borrowings – Short term liabilities 1,150,470 1,150,470 Total current liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 3,505,322 7 Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity 11,898,945 11,898,945 Issued capital 11,898,945 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -		<u>-</u>	399,987
Borrowings - Short term liabilities			-
Total current liabilities 2,494,674 4,975,683 Non-current liabilities 245,971 1,398,224 Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 3,505,322 Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity 11,898,945 11,898,945 Reserves 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -			820,451
Non-current liabilities Deferred tax liabilities 245,971 1,398,224 Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 3,505,322 Total non-current liabilities 4,241,690 4,789,282 Net assets 2,870,658 8,774,672 Equity Issued capital 11,898,945 11,898,945 Reserves 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -			4.000
Deferred tax liabilities 245,971 1,398,224 Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 3,505,322 Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity 11,898,945 11,898,945 Issued capital 11,898,945 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -		2,494,674	4,975,683
Lease – Long term liabilities 490,397 3,391,058 Borrowings – Long term liabilities 3,505,322 Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity 11,898,945 11,898,945 Reserves 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -		0.45.054	4 000 004
Borrowings - Long term liabilities 3,505,322 4,241,690 4,789,282 Total non-current liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity			
Total non-current liabilities 4,241,690 4,789,282 Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity 11,898,945 11,898,945 11,898,945 Reserves 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -			3,391,058
Total liabilities 6,736,364 9,764,965 Net assets 2,870,658 8,774,672 Equity 11,898,945 11,898,945 11,898,945 Reserves 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -			4 700 000
Net assets 2,870,658 8,774,672 Equity 11,898,945 11,898,945 Issued capital 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group 2,886,748 8,774,672 Non-controlling interests (16,090) -			4,789,282
Equity ssued capital	Total liabilities	6,736,364	9,764,965
Issued capital	Net assets	2,870,658	8,774,672
Issued capital			
Reserves 2,186,367 1,643,838 (Accumulated losses) (11,198,564) (4,768,111) Total equity attributable to member of the Group Non-controlling interests 2,886,748 8,774,672 (16,090) -			
(Accumulated losses)(11,198,564)(4,768,111)Total equity attributable to member of the Group Non-controlling interests2,886,748 (16,090)8,774,672 -			
Total equity attributable to member of the Group Non-controlling interests 2,886,748 8,774,672 (16,090)		· · · · · · · · · · · · · · · · · · ·	
Non-controlling interests (16,090) -	(Accumulated losses)	(11,198,564)	(4,768,111)
Non-controlling interests (16,090) -	Total equity attributable to member of the Group	2,886,748	8,774,672
Total equity 2,870,658 8,774,672	Non-controlling interests		<u> </u>
	Total equity	2,870,658	8,774,672

Mediland Pharm Limited Consolidated Statement of cash flows For the year ended 30 June 2021

Cash flows from operating activities	Consoli 2021 \$	dated 2020 \$
CASU BOWS HOLLI ODERANIO ACHVINES	Ψ	Φ
Receipts from customers (inclusive of GST)	687,779	24,271,223
Payments to suppliers and employees (inclusive of GST)	(3,867,336)	(25,773,774)
Interest received	58,334	109,722
Lease interests	(129,387)	(180,526)
Net income taxes refunded/(paid)	338,642	(547,635)
Government grants and tax incentives	629,753	288,984
Government grants and tax incentives	029,700	200,904
Net cash used in operating activities	(2,282,215)	(1,832,006)
Cash flows from investing activities		
Proceeds from disposal of plant and equipment	-	1,818
Payments to acquire plant and equipment	(4,342)	(1,319,481
Purchase of intangibles	<u>-</u>	(112,325
Payments to acquire business	(300,000)	(800,000
Payment to related party	(97,976)	•
Loss of control over subsidiaries	(876,306)	
Net cash used in investing activities	(1,278,624)	(2,229,988
Cash flows from financing activities		
Lease payment (Principal)	(340,173)	(622,346)
Ecase payment (i finoipai)	(040,170)	(022,040)
Net cash used in financing activities	(340,173)	(622,346)
Net decrease in cash and cash equivalents	(3,901,012)	(4,684,340
Cash and cash equivalents at the beginning of the financial year	7,304,139	12,047,350
Effects of exchange rate changes on cash and cash equivalents	(12,052)	(58,871
Cash and cash equivalents at the end of the financial year	3,391,075	7,304,139

Mediland Pharm Limited Consolidated statement of changes in equity For the year ended 30 June 2021

	Issued capital	Group restructure reserve	Foreign currency reserve	Share-based payments reserve	Retained Profits/ (Accumulated losses)	Total equity
Consolidated	\$	\$	\$	\$	\$	\$
Balance at 1 July 2019	11,898,945	71,146	18,164	710,909	341,427	13,040,591
Reversal of share-based payment (note 18)	· · · · -	· <u>-</u>	· <u>-</u>	(74,218)	74,218	· · · -
Impact of change in accounting policy – AASB16	-	-	-	-	(74,715)	(74,715)
Restated balance at 1 July 2019	11,898,945	71,146	18,164	636,691	340,930	12,965,876
Loss after income tax expense for the year	_	-	-	-	(5,109,041)	(5,109,041)
Other comprehensive income for the year, net of tax		-	(72,723)	<u>-</u>	<u> </u>	(72,723)
Total comprehensive income for the year	-	-	(72,723)	-	(5,109,041)	(5,181,764)
Transactions with owners in their capacity as owners: Share-based payments				990,560	<u> </u>	990,560
Balance at 30 June 2020	11,898,945	71,146	(54,559)	1,627,251	(4,768,111)	8,774,672

Mediland Pharm Limited Consolidated statement of changes in equity For the year ended 30 June 2021

	Issued capital	Group restructure reserve	Foreign currency reserve	Share-based payments reserve	(Accumulated losses)	Total	Non- controlling Interest	Total equity
Consolidated	\$	\$	\$	\$	\$	\$	\$	\$
Balance at 1 July 2020	11,898,945	71,146	(54,559)	1,627,251	(4,768,111)	8,774,672	-	8,774,672
Loss after income tax expense for the year Other comprehensive income for the year, net of	-	-	-	-	(6,430,453)	(6,430,453)	(16,090)	(6,446,543)
tax			(9,782)			(9,782)	-	(9,782)
Total comprehensive income for the year	-	-	(9,782)	-	(6,430,453)	(6,440,235)	(16,090)	(6,456,325)
Transactions with owners in their capacity as owners:								
Share-based payments				552,311		552,311	-	552,311
Balance at 30 June 2021	11,898,945	71,146	(64,341)	2,179,562	(11,198,564)	2,886,748	(16,090)	2,870,658